FDA Funding In Cures Bill Complicated By Metrics, Appropriators
This article was originally published in The Gray Sheet
Executive Summary
The wide-ranging reforms in the House 21st Century Cures bill have attracted a good measure of bipartisan support, but the lack of extra funding for FDA continues to be a source of tension.